{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:37:26Z","timestamp":1775734646398,"version":"3.50.1"},"reference-count":194,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Radiology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jacr.2022.09.005","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T09:44:24Z","timestamp":1669369464000},"page":"S390-S408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S","title":["ACR Appropriateness Criteria\u00ae Management of Liver Cancer: 2022 Update"],"prefix":"10.1016","volume":"19","author":[{"given":"Erica M.","family":"Knavel Koepsel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda R.","family":"Smolock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason W.","family":"Pinchot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osmanuddin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murthy R.K.","family":"Chamarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria L.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Join Y.","family":"Luh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Marrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Poultsides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Scheidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Hohenwalter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacr.2022.09.005_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jacr.2022.09.005_bib3","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2009.12.032","article-title":"The place of downstaging for hepatocellular carcinoma","volume":"52","author":"Toso","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.gassur.2005.09.008","article-title":"Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality","volume":"9","author":"Teh","year":"2005","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jamcollsurg.2007.01.069","article-title":"Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience","volume":"205","author":"Yamashita","year":"2007","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cld.2015.01.007","article-title":"Surgical resection and liver transplantation for hepatocellular carcinoma","volume":"19","author":"Akoad","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jacr.2022.09.005_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.surg.2007.05.009","article-title":"Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients","volume":"142","author":"Taura","year":"2007","journal-title":"Surgery"},{"key":"10.1016\/j.jacr.2022.09.005_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/02656736.2016.1209694","article-title":"Microwave ablation in primary and secondary liver tumours: technical and clinical approaches","volume":"33","author":"Meloni","year":"2017","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.jacr.2022.09.005_bib10","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/tri.12297","article-title":"Living donor liver transplantation or resection for Child-Pugh A hepatocellular carcinoma patients with multiple nodules meeting the Milan criteria","volume":"27","author":"Jiang","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.jacr.2022.09.005_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jso.23531","article-title":"Transplant versus resection for the management of hepatocellular carcinoma meeting Milan criteria in the MELD exception era at a single institution in a UNOS region with short wait times","volume":"109","author":"Squires","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib13","first-page":"CD011650","article-title":"Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis","volume":"3","author":"Majumdar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacr.2022.09.005_bib14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ajg.2008.80","article-title":"Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials","volume":"104","author":"Orlando","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacr.2022.09.005_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","article-title":"A\u00a0prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma","volume":"243","author":"Chen","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A\u00a0randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"Feng","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jvir.2012.12.009","article-title":"Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience","volume":"24","author":"Fujimori","year":"2013","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","article-title":"A\u00a0randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria","volume":"252","author":"Huang","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.21933","article-title":"Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?","volume":"47","author":"Livraghi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jacr.2022.09.005_bib20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1148\/radiol.11110817","article-title":"Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study","volume":"262","author":"Peng","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jacr.2022.09.005_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1477-2574.2012.00541.x","article-title":"Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma","volume":"15","author":"Tohme","year":"2013","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jacr.2022.09.005_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818790217","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: current trends and controversies","volume":"17","author":"Schaub","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jacr.2022.09.005_bib23","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jacr.2022.09.005_bib24","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study","volume":"45","author":"Mendez Romero","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12094-010-0492-x","article-title":"Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma","volume":"12","author":"Cardenes","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/hepr.13647","article-title":"Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: systematic review and meta-analysis of propensity score studies","volume":"51","author":"Eriguchi","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jacr.2022.09.005_bib28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3389\/fonc.2020.01639","article-title":"Stereotactic body radiotherapy vs. radiofrequency ablation in the treatment of hepatocellular carcinoma: a meta-analysis","volume":"10","author":"Pan","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/1754-9485.12754","article-title":"Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: an analysis of SEER-medicare","volume":"62","author":"Parikh","year":"2018","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib30","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.2017.75.3228","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the National Cancer Database","volume":"36","author":"Rajyaguru","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib31","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1002\/cam4.893","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis","volume":"5","author":"Seo","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib32","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A\u00a0comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacr.2022.09.005_bib33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ijrobp.2011.08.032","article-title":"Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation","volume":"83","author":"Katz","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jacr.2022.09.005_bib34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/lt.23439","article-title":"Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation","volume":"18","author":"O\u2019Connor","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacr.2022.09.005_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.adro.2015.12.003","article-title":"Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma","volume":"1","author":"Mohamed","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.21037\/tgh.2017.11.18","article-title":"Downstaging for hepatocellular cancer: harm or benefit?","volume":"2","author":"Bryce","year":"2017","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3748\/wjg.v11.i2.200","article-title":"Detection of hypervascular hepatocellular carcinoma: Comparison of multi-detector CT with digital subtraction angiography and Lipiodol CT","volume":"11","author":"Zheng","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacr.2022.09.005_bib38","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.crad.2006.05.011","article-title":"Technical report: Lipiodol-guided computed tomography for radiofrequency ablation of hepatocellular carcinoma","volume":"61","author":"Gandhi","year":"2006","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacr.2022.09.005_bib40","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study","volume":"57","author":"Mazzaferro","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jacr.2022.09.005_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.semnuclmed.2019.01.003","article-title":"The role of radioembolization in bridging and downstaging hepatocellular carcinoma to curative therapy","volume":"49","author":"Titano","year":"2019","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib42","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jacr.2022.09.005_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/hep.27057","article-title":"Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy","volume":"60","author":"Vouche","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jacr.2022.09.005_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","article-title":"Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization","volume":"79","author":"Riaz","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jacr.2022.09.005_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejrad.2017.05.022","article-title":"Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization","volume":"93","author":"Gabr","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/jso.20609","article-title":"Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation","volume":"94","author":"Kulik","year":"2006","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib47","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience","volume":"68","author":"Salem","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacr.2022.09.005_bib48","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: a systematic review and pooled analysis","volume":"21","author":"Parikh","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacr.2022.09.005_bib49","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/0284185115603246","article-title":"Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center","volume":"57","author":"Bharadwaz","year":"2016","journal-title":"Acta Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.dld.2014.12.007","article-title":"Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma","volume":"47","author":"Iezzi","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jacr.2022.09.005_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MEG.0b013e32835a0a07","article-title":"Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials","volume":"25","author":"Lu","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib52","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1148\/radiol.11110637","article-title":"Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial","volume":"262","author":"Peng","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jacr.2022.09.005_bib53","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/MEG.0000000000000688","article-title":"Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: a randomized-controlled study","volume":"28","author":"Sheta","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hep.22412","article-title":"Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis","volume":"48","author":"Yao","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jacr.2022.09.005_bib55","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1186\/1471-2407-14-849","article-title":"Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma","volume":"14","author":"Yin","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib56","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"suppl 2","key":"10.1016\/j.jacr.2022.09.005_bib57","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacr.2022.09.005_bib58","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.crad.2015.06.092","article-title":"High-powered microwave ablation of larger hepatocellular carcinoma: evaluation of recurrence rate and factors related to recurrence","volume":"70","author":"Zhang","year":"2015","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib59","first-page":"456","article-title":"Value of microwave ablation in treatment of large lesions of hepatocellular carcinoma","volume":"16","author":"Medhat","year":"2015","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.jacr.2022.09.005_bib60","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"Brown","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib61","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/lt.23846","article-title":"Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation","volume":"20","author":"Kluger","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacr.2022.09.005_bib62","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jvir.2008.02.013","article-title":"Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma","volume":"19","author":"Maluccio","year":"2008","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib64","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jso.21522","article-title":"Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)","volume":"101","author":"Dhanasekaran","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib65","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/jgh.12439","article-title":"Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"29","author":"Huang","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib67","first-page":"255","article-title":"Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review","volume":"59","author":"Martin","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jacr.2022.09.005_bib68","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacr.2022.09.005_bib69","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jacr.2022.09.005_bib70","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ejca.2008.01.004","article-title":"Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402)","volume":"44","author":"Doffoel","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial","volume":"29","author":"Pelletier","year":"1998","journal-title":"Groupe CHC. J Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib72","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A\u00a0comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma","volume":"332","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1245\/s10434-010-1288-5","article-title":"Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study","volume":"18","author":"Martin","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib74","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2012.09.021","article-title":"Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate","volume":"58","author":"Cescon","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib75","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/SLA.0b013e31818a07d4","article-title":"Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation","volume":"248","author":"Chapman","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib76","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1478-3231.2009.02166.x","article-title":"Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma","volume":"30","author":"Chua","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jacr.2022.09.005_bib77","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/lt.22039","article-title":"Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria","volume":"16","author":"De Giorgio","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacr.2022.09.005_bib78","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1245\/s10434-008-0071-3","article-title":"Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation","volume":"15","author":"Heckman","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib79","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/j.1600-6143.2006.01509.x","article-title":"Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis","volume":"6","author":"Lesurtel","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacr.2022.09.005_bib80","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/lt.20099","article-title":"Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization","volume":"10","author":"Maddala","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacr.2022.09.005_bib81","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cld.2015.01.008","article-title":"Locoregional therapy of hepatocellular carcinoma","volume":"19","author":"Habib","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jacr.2022.09.005_bib82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/TP.0000000000002835","article-title":"Outcomes of liver transplantation for hepatocellular carcinoma beyond the University of California San Francisco criteria: a single-center experience","volume":"104","author":"Victor","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.jacr.2022.09.005_bib83","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/jgh.12088","article-title":"Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy","volume":"28","author":"Xu","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib84","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3109\/02656736.2011.605099","article-title":"MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma","volume":"27","author":"Liu","year":"2011","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.jacr.2022.09.005_bib85","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib87","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib88","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacr.2022.09.005_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000714","article-title":"Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial","volume":"5","author":"Kelley","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.jacr.2022.09.005_bib90","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib91","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacr.2022.09.005_bib92","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00270-012-0458-1","article-title":"Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies","volume":"36","author":"Bova","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1477-2574.2010.00228.x","article-title":"Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation","volume":"13","author":"DuBay","year":"2011","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jacr.2022.09.005_bib94","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/jlts.2003.50106","article-title":"Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome","volume":"9","author":"Graziadei","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacr.2022.09.005_bib95","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/SLA.0b013e31818eec29","article-title":"The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review","volume":"249","author":"Lau","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib96","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1600-6143.2008.02409.x","article-title":"Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria","volume":"8","author":"Ravaioli","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacr.2022.09.005_bib97","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.transproceed.2004.07.068","article-title":"The significance of transarterial embolization for advanced hepatocellular carcinoma in liver transplantation","volume":"36","author":"Sun","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jacr.2022.09.005_bib98","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/COC.0000000000000435","article-title":"Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: high rates of local control with low toxicity","volume":"41","author":"Baumann","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib99","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.32502","article-title":"A\u00a0phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy","volume":"126","author":"Jang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib100","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00261-014-0094-0","article-title":"Ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinoma guided by automated tumor-feeders detection software: technical success and short-term tumor response","volume":"39","author":"Miyayama","year":"2014","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.jacr.2022.09.005_bib101","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jvir.2006.12.004","article-title":"Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil","volume":"18","author":"Miyayama","year":"2007","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib102","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study","volume":"116","author":"Carr","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib103","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jvir.2009.10.013","article-title":"Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma","volume":"21","author":"Kooby","year":"2010","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib104","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","article-title":"Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma","volume":"22","author":"Lance","year":"2011","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib105","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00270-016-1426-y","article-title":"Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis","volume":"39","author":"Lobo","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib106","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","article-title":"Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma","volume":"36","author":"Moreno-Luna","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib107","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","author":"Salem","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacr.2022.09.005_bib108","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation","volume":"54","author":"Sangro","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jacr.2022.09.005_bib109","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00259-016-3438-x","article-title":"Same-day Y radioembolization: implementing a new treatment paradigm","volume":"43","author":"Gabr","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jacr.2022.09.005_bib110","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jvir.2013.11.005","article-title":"Outpatient single-session yttrium-90 glass microsphere radioembolization","volume":"25","author":"Gates","year":"2014","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib111","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","article-title":"Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma","volume":"260","author":"Zhong","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib112","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ctr.12755","article-title":"Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation","volume":"30","author":"Andreou","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jacr.2022.09.005_bib113","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/liv.12966","article-title":"Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy","volume":"36","author":"Finkenstedt","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jacr.2022.09.005_bib114","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-230X-13-60","article-title":"Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis","volume":"13","author":"Xue","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jacr.2022.09.005_bib115","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s12032-011-0145-0","article-title":"Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification","volume":"29","author":"Niu","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib116","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study","volume":"18","author":"Luo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib117","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib118","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib119","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.suronc.2017.03.001","article-title":"Multidisciplinary management of intrahepatic cholangiocarcinoma: current approaches","volume":"26","author":"Guro","year":"2017","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib121","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17474124.2018.1489229","article-title":"Challenges of surgical management of intrahepatic cholangiocarcinoma","volume":"12","author":"Squires","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib122","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/00007890-200004270-00019","article-title":"Liver transplantation for cholangiocarcinoma: results in 207 patients","volume":"69","author":"Meyer","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.jacr.2022.09.005_bib123","doi-asserted-by":"crossref","first-page":"W205","DOI":"10.2214\/AJR.10.4937","article-title":"Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma","volume":"196","author":"Kim","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2022.09.005_bib124","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2217\/fon-2017-0022","article-title":"Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma","volume":"13","author":"Mosconi","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1259\/bjr\/24563774","article-title":"Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma","volume":"85","author":"Xu","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib126","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jvir.2015.02.024","article-title":"Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"26","author":"Han","year":"2015","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib127","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option","volume":"17","author":"Saxena","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/hpb.12450","article-title":"Hilar cholangiocarcinoma: expert consensus statement","volume":"17","author":"Mansour","year":"2015","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jacr.2022.09.005_bib129","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","article-title":"Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis","volume":"20","author":"Hyder","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib130","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jvir.2013.03.019","article-title":"Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma","volume":"24","author":"Ray","year":"2013","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib131","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00432-016-2291-4","article-title":"Resin-based yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results","volume":"143","author":"Jia","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib132","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.tvir.2019.02.008","article-title":"Y90 clinical data update: cholangiocarcinoma, neuroendocrine tumor, melanoma, and breast cancer metastatic disease","volume":"22","author":"Padia","year":"2019","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib133","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/jgh.13752","article-title":"Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors","volume":"32","author":"Jia","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib134","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jacr.2022.09.005_bib135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00270-004-4082-6","article-title":"Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques","volume":"28","author":"Atwell","year":"2005","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib136","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-020-00784-0","article-title":"Updated efficacy and safety outcomes for patients with well-differentiated pancreatic neuroendocrine tumors treated with sunitinib","volume":"16","author":"Fazio","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib137","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacr.2022.09.005_bib138","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacr.2022.09.005_bib139","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","article-title":"Hepatic resection for metastatic neuroendocrine carcinomas","volume":"169","author":"Que","year":"1995","journal-title":"Am J Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib141","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib142","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.suronc.2012.05.001","article-title":"Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review","volume":"21","author":"Saxena","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib143","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jamcollsurg.2013.12.035","article-title":"A\u00a0single institution\u2019s experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors","volume":"218","author":"Boudreaux","year":"2014","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib144","first-page":"1091","article-title":"Cytoreductive hepatic surgery for neuroendocrine tumors","volume":"108","author":"McEntee","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.jacr.2022.09.005_bib145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.surg.2017.05.006","article-title":"Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review","volume":"162","author":"Moris","year":"2017","journal-title":"Surgery"},{"key":"10.1016\/j.jacr.2022.09.005_bib146","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib147","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/107327481001700205","article-title":"Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy","volume":"17","author":"Hoffe","year":"2010","journal-title":"Cancer Control"},{"key":"10.1016\/j.jacr.2022.09.005_bib148","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.7314\/APJCP.2015.16.15.6381","article-title":"Whole liver palliative radiotherapy for patients with massive liver metastases","volume":"16","author":"Edyta","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jacr.2022.09.005_bib149","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib150","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jvir.2007.04.018","article-title":"Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver","volume":"18","author":"Ruutiainen","year":"2007","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"suppl 1","key":"10.1016\/j.jacr.2022.09.005_bib151","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1007\/s12032-010-9750-6","article-title":"Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients","volume":"28","author":"Dong","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib152","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00270-012-0424-y","article-title":"Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury","volume":"36","author":"Bhagat","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib153","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","article-title":"Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors","volume":"47","author":"Fiore","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.jacr.2022.09.005_bib154","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.2967\/jnumed.113.135855","article-title":"The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis","volume":"55","author":"Devcic","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ajco.12438","article-title":"Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes","volume":"12","author":"Pericleous","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib156","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cct.2016.08.001","article-title":"Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization","volume":"50","author":"Fan","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jacr.2022.09.005_bib157","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","article-title":"Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads","volume":"56","author":"Guiu","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacr.2022.09.005_bib158","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00270-016-1478-z","article-title":"Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival","volume":"40","author":"Chen","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib159","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jvir.2018.02.002","article-title":"Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases","volume":"29","author":"Tomozawa","year":"2018","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib160","article-title":"Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience","volume":"2012","author":"Filice","year":"2012","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib161","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib162","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacr.2022.09.005_bib163","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-4939-7765-9_18","article-title":"Molecular testing for the treatment of advanced colorectal cancer: an overview","volume":"1765","author":"Lin","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jacr.2022.09.005_bib164","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7150\/ijms.24453","article-title":"New trends in the therapeutic approach to metastatic colorectal cancer","volume":"15","author":"Sanchez-Gundin","year":"2018","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jacr.2022.09.005_bib165","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.ejca.2012.12.011","volume":"49","author":"Ducreux","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib166","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib167","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A\u00a0randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib168","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib169","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3748\/wjg.v22.i11.3127","article-title":"Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases","volume":"22","author":"Sag","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"suppl 2","key":"10.1016\/j.jacr.2022.09.005_bib170","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.ejso.2007.09.017","article-title":"Bringing unresectable liver disease to resection with curative intent","volume":"33","author":"Wicherts","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib171","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000335713","article-title":"How much remnant is enough in liver resection?","volume":"29","author":"Guglielmi","year":"2012","journal-title":"Dig Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib172","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/lt.24791","article-title":"Liver transplantation for colorectal liver metastasis: Survival without recurrence can be achieved","volume":"23","author":"Toso","year":"2017","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacr.2022.09.005_bib173","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00330-004-2416-z","article-title":"Radio-frequency ablation of colorectal liver metastases in 167 patients","volume":"14","author":"Gillams","year":"2004","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib174","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/archsurg.2011.212","article-title":"Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis","volume":"146","author":"Khajanchee","year":"2011","journal-title":"Arch Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib175","first-page":"e183","article-title":"Survival and prognostic factors of colorectal liver metastases after surgical and nonsurgical treatment","volume":"15","author":"Lemke","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib176","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1148\/radiol.2015142489","article-title":"Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes\u2014a 10-year experience at a single center","volume":"278","author":"Shady","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jacr.2022.09.005_bib177","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00432-018-2692-7","article-title":"Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation","volume":"144","author":"Franzese","year":"2018","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib178","first-page":"37","article-title":"Initial experience with the use of preoperative transarterial chemoembolization in the treatment of liver metastasis","volume":"96","author":"Ceelen","year":"1996","journal-title":"Acta Chir Belg"},{"key":"10.1016\/j.jacr.2022.09.005_bib179","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00270-016-1547-3","article-title":"Radiofrequency ablation combined with hepatic arterial chemoembolization using degradable starch microsphere mixed with mitomycin C for the treatment of liver metastasis from colorectal cancer: a prospective multicenter study","volume":"40","author":"Yamakado","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib180","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib181","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jacr.2022.09.005_bib182","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1002\/cncr.25997","article-title":"Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis","volume":"117","author":"Chang","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib183","first-page":"308","article-title":"Hepatic arterial infusion chemotherapy for unresectable liver metastases of colorectal cancer: a multicenter retrospective study","volume":"16","author":"Lim","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib184","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3748\/wjg.v23.i8.1406","article-title":"Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis","volume":"23","author":"Guo","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacr.2022.09.005_bib185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes","volume":"261","author":"D\u2019Angelica","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacr.2022.09.005_bib186","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.suronc.2015.06.014","article-title":"Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases","volume":"24","author":"Chan","year":"2015","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib187","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jvir.2012.06.031","article-title":"Phase I\/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI","volume":"23","author":"Arai","year":"2012","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib188","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jvir.2013.05.055","article-title":"Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review","volume":"24","author":"Richardson","year":"2013","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib189","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cncr.25387","article-title":"Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol","volume":"117","author":"Albert","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib190","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib191","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer","volume":"34","author":"van Hazel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2022.09.005_bib192","first-page":"e617","article-title":"Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies","volume":"17","author":"Gibbs","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jacr.2022.09.005_bib193","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00270-011-0234-7","article-title":"Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases","volume":"35","author":"Seidensticker","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jacr.2022.09.005_bib194","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.bjc.6605770","article-title":"Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases","volume":"103","author":"Cosimelli","year":"2010","journal-title":"Br J Cancer"}],"container-title":["Journal of the American College of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1546144022006391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1546144022006391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:31:27Z","timestamp":1761546687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1546144022006391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":194,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1546144022006391"],"URL":"https:\/\/doi.org\/10.1016\/j.jacr.2022.09.005","relation":{},"ISSN":["1546-1440"],"issn-type":[{"value":"1546-1440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACR Appropriateness Criteria\u00ae Management of Liver Cancer: 2022 Update","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacr.2022.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Radiology","name":"copyright","label":"Copyright"}]}}